About Sirion Biotech
Sirion Biotech is a viral vector technology company for gene and cell therapy. The company offers platforms based on lentiviruses, adenoviruses, and adeno-associated viruses (AAV) custom engineering, and manufacturing to expedite gene therapy research, cell therapy research, and advanced drug development. It was founded in 2007 and is based in Martinsried, Germany. On June 22, 2021, Sirion Biotech was acquired by PerkinElmer.
Sirion Biotech Patents
Sirion Biotech has filed 10 patents.
Transcription factors, Molecular biology, Clusters of differentiation, Biotechnology, Developmental biology
Transcription factors, Molecular biology, Clusters of differentiation, Biotechnology, Developmental biology
Latest Sirion Biotech News
Aug 24, 2023
" - https://www.reportlinker.com/p06486473/?utm_source=GNW , Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Hoffmann-La Roche AG, Catalent Inc., System Biosciences LLC, and Avantor. The global gene delivery technologies market is expected to grow from $3.10 billion in 2022 to $3.57 billion in 2023 at a compound annual growth rate (CAGR) of 15.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gene delivery technologies market is expected to reach $6.11 billion in 2027 at a CAGR of 14.3%. The gene delivery technologies market consists of revenues earned by entities by providing services such as viral vector production, gene editing, gene therapy, and cell therapy.The market value includes the value of related goods sold by the service provider or included within the service offering. Gene delivery technologies also include sales of viral and non-viral vectors, transfection reagents, gene editing tools that are used in providing gene delivery.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. Gene delivery technologies refer to methods that are used to introduce foreign genetic material, such as DNA or RNA, into cells, where the goal of gene delivery is to transfer the genetic material into the target cells. These technologies are commonly used in treating diseases or disorders caused by changed gene-like mutations or an inherited gene. North America was the largest region in the gene delivery technologies market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene delivery technologies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The main gene delivery technologies mode types are biological, chemical, and physical.Biological refers to the use of living organisms or their products in the development and delivery of gene therapy products. The various methods are ex vivo, in vivo, and in vitro applied in gene therapy, cell therapy, vaccines, and research. The increasing number of cell and gene therapies is expected to propel the growth of the gene delivery technologies market going forward.Cell and gene therapies refer to medical treatments that aim to cure or alleviate diseases by altering a patient’s body’s genetic and cellular makeup. The increasing number of cell and gene therapies is mainly driven by advancements in gene editing technologies, playing a critical role in developing and commercializing cell and gene therapies.For instance, in October 2022, according to an article published by Economist Impact, a UK-based corporation empowering businesses, governments, and foundations to catalyze change and enable progress, in mid-2021 around 2,600 clinical trials for CGTs were underway. Companies have conducted over half of it since 2015, and these have increased as per their research demand in multiple fields.Researchers estimate that by 2031, the United States will have 100 approved CGTs. Additionally, between 2022 and 2031, the FDA is expected to approve 8 or 9 CGTs per year on average. Therefore, increasing cell and gene therapies drives the gene delivery technologies market. Technological advancement has emerged as a key trend gaining popularity in the gene delivery technologies market.Major market players are concentrating their efforts on creating technologically advanced products to strengthen their position in the market. For instance, in February 2023, Aera Therapeutics, a US-based biotechnology company, launched Aera’s Platform delivery technology to unlock the potential of genetic medicines.Aera’s PNP technology allows for the precise targeting of RNA molecules that are involved in disease processes. This technology allows for the targeted editing of genes in a patient’s cells, offering the potential for personalized gene therapies. In June 2021, a US-based company involved in diagnostics and life sciences, PerkinElmer, acquired SIRION Biotech for an undisclosed amount.The acquisition was aimed at expanding PerkinElmer’s capabilities in gene therapy and viral vector technologies, which are crucial to the development of gene therapies for various diseases, and it will also strengthen the company’s position as a provider of gene delivery technologies, enabling it to serve the growing demand for gene therapies better. SIRION Biotech is a German-based provider of viral vector and gene delivery therapy. The countries covered in the gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The gene delivery technologies market research report is one of a series of new reports that provides gene delivery technologies market statistics, including gene delivery technologies industry global market size, regional shares, competitors with a gene delivery technologies market share, detailed gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the gene delivery technologies industry. This gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sirion Biotech Frequently Asked Questions (FAQ)
When was Sirion Biotech founded?
Sirion Biotech was founded in 2007.
Where is Sirion Biotech's headquarters?
Sirion Biotech's headquarters is located at Am Klopferspitz 19, Martinsried.
What is Sirion Biotech's latest funding round?
Sirion Biotech's latest funding round is Acquired.
Who are the investors of Sirion Biotech?
Investors of Sirion Biotech include PerkinElmer, Bayern Kapital, KfW, Creathor Ventures, High-Tech Grunderfonds and 3 more.
Who are Sirion Biotech's competitors?
Competitors of Sirion Biotech include Bio Design Lab, MetaBiologics, Amnis Corporation, WaferGen Bio-systems, HTG Molecular Diagnostics and 13 more.
Compare Sirion Biotech to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.
Bio::Neos aims to provide bioinformatics software tools to aid commercial and academic research groups in efficiently and effectively performing genomics-enabled research. The company specialize in mutation identification research and custom software solutions specifically developed to meet the needs of research groups of any size.
Plexigen is developing a 3-D biochip to enhance the capacity, efficiency, accuracy, and automation of gene screening. The technology was originally developed at North Carolina State University.
Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.
American Biosystems, Inc., produces and markets biological products used in Agriculture, Aquaculture and Industry. Specialized bacterial cultures are grown and harvested to produce enzymes ... nature's catalysts. These products can be incorporated into animal feed as a natural alternative to hormones and antibiotics while providing many of the same benefits. For Aquaculture, bacteria digest uneaten feed and waste products, providing cleaner water and producing less stress on farm-raised shrimp. For Industry, target markets include complex manufacturing processes, bio-medical cleaning products, waste reduction and recycling. Bacteria and the enzymes they produce are nature's way of breaking down wastes into harmless components or building blocks man can use to rebuild or remake other products. The company was founded in 1982 by Lewis E. Goyette, Ph.D, and is now managed by his son Edward M. Goyette. The company markets in over 15 countries through overseas distributors and currently has two employees in The New Century Venture Center. American Biosystems moved into the center on May 31, 2002.